ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment

ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment

2025.02.17
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, bringing together global experts to discuss the latest advancements in hematology. During this prestigious event, Dr. Minghui Duan from Peking Union Medical College Hospital presented his team’s latest findings on myelofibrosis (MF) treatment (Abstract #1002), offering new perspectives for future therapeutic strategies. To provide deeper insights, Hematology Frontier invited Professor Duan for an in-depth discussion on his research.
ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins

2025.02.17
Minimal residual disease (MRD) is a powerful predictor of relapse in acute myeloid leukemia (AML), yet its accuracy remains a challenge. Some patients who are MRD-positive do not relapse, while others who are MRD-negative still experience disease recurrence. At the 2024 American Society of Hematology (ASH) Annual Meeting, Professor Jerald Radich from Fred Hutchinson Cancer Center provided an in-depth analysis of how mutations, clonal architecture, and disease evolution influence treatment response, resistance, and relapse.To clarify the complex relationship between MRD and clonal dynamics, Hematology Frontier has compiled key insights from this discussion.
Case Compilation | The Battle of Outstanding Clinical Cases

Case Compilation | The Battle of Outstanding Clinical Cases

2025.02.17
Lung cancer remains the most common and deadliest malignancy in China. Optimizing treatment strategies is essential for extending patient survival and improving quality of life. In the era of precision medicine, targeted therapies such as icotinib and befotertinib have provided significant breakthroughs for non-small cell lung cancer (NSCLC), demonstrating the commitment and innovation of Chinese pharmaceutical companies in the global fight against cancer.
ASCO GU 2025 | Dr. Jianming Guo & Dr. Philip Kwong Share Advances in mCRPC Research, Paving the Way for Future Diagnosis and Treatment Strategies

ASCO GU 2025 | Dr. Jianming Guo & Dr. Philip Kwong Share Advances in mCRPC Research, Paving the Way for Future Diagnosis and Treatment Strategies

2025.02.17
The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium  (ASCO GU 2025) is currently taking place in San Francisco, USA. This globally renowned academic conference brings together top oncology experts to explore cutting-edge breakthroughs and future directions in the field of genitourinary cancers. On-site at ASCO GU, Urology Frontier invited Dr. Jianming Guo from Zhongshan Hospital, Fudan University, to engage in a discussion with Dr. Philip Kwong from The University of Hong Kong. Together, they analyzed key advancements in metastatic castration-resistant prostate cancer (mCRPC), covering treatment strategies, novel ADC drugs, precision medicine, and radioligand therapy.